Prescription of Preexposure Prophylaxis to Men Who Have Sex With Men Diagnosed and Reported With Gonorrhea, STD Surveillance Network, 2016.

Using a representative sample of gonorrhea cases in select jurisdictions, we estimated the proportion of eligible men who have sex with men reporting being prescribed preexposure prophylaxis (PrEP) to prevent HIV infection. In 2016, half (51.3%) of the estimated 33,165 eligible men who have sex with men reported being prescribed PrEP by their health care provider.

Assessing the interest to participate in a dengue vaccine efficacy trial among residents of Puerto Rico.

Dengue, endemic in Puerto Rico, is a major public health problem. Vaccines are thought the best means to prevent dengue because vector control alone has been largely ineffective. We implemented qualitative studies in 2006 and 2010 to determine the acceptability of conducting placebo-controlled dengue vaccine efficacy trials in Puerto Rican children. Key informant interviews and focus groups with parents and children were conducted in municipalities with high dengue incidence. We used structured open-ended questions to determine motivators and attitudes regarding vaccine trial participation. Knowledge about dengue risk and prevention, and knowledge, attitudes, and beliefs regarding vaccines and vaccine trials were assessed. Using grounded theory, we conducted content analysis and established categories and sub-categories of participant responses. All participants were knowledgeable about dengue prevention and perceived children as most affected age groups. Participants were aware of vaccines benefits and they thought a vaccine could prevent dengue. However, most would not allow their children to participate in a placebo-controlled vaccine trial. Barriers included lack of trust in new vaccines and vaccine trial procedures; fear of developing dengue or side effects from the vaccine and lack of information about candidate dengue vaccines. Participants thought information, including results of previous trials might overcome barriers to participation. Motivators for participation were altruism, protection from dengue, free medical attention, and compensation for transportation and participation. Parents would consider children participation if accurate vaccine trial information is provided.

Economic cost of dengue public prevention activities in Puerto Rico.

Dengue fever has become a major global public health problem in Puerto Rico. Approximately 5000 suspected cases were reported annually between 2002 and 2007. Vector control is currently the only approach to control the disease and includes prevention education, fumigation, inspections and clean-up campaigns. The annual cost to the public sector of dengue prevention, which includes surveillance and vector control activities, was estimated as part of a study of the economic burden of dengue in Puerto Rico. A telephonic survey was implemented to identify municipalities with vector control programmes and public agencies with dengue surveillance systems. Onsite interviews were conducted using a structured questionnaire. The economic cost of dengue was summarized by line item, function and year from 2002 through 2007. The Puerto Rico Department of Health (PRDH) and 12 municipalities out of 78 conducted vector control activities in different magnitudes during the study years. The cumulative cost of dengue vector control in the public sector was US$ 46.22 million for the years 2002–2007. PRDH spent an average of US$ 1.29 million ($0.33 per capita) per year, while the municipalities spent an average of US$ 6.41 million (US$ 1.64 per capita) per year. Clean-up campaigns had the highest share of average expenditure, followed by fumigation, surveillance and inspection. Puerto Rico’s per capita expenditure on dengue prevention activities is similar to that of other countries in the region. On average, Puerto Rico’s per capita spending on dengue illness is US$ 5.48 compared with US$ 1.97 spent on vector control.